The mechanism of action of C-reactive protein (CRP) in protecting mice against lethal 21
INTRODUCTION 39
7 endotoxin units (EU) and 4.64±2.19 EU, respectively. The endotoxin content in 25 g and 150 115 µg mutant CRP was 0.53±0.28 EU and 3.22±1.65 EU, respectively. After 30 min, mice were 116 injected i.v. with either 10 7 CFU or 5 x 10 7 CFU of pneumococci in 100 l of saline. Survival of 117 mice was recorded three times per day for 10 days. Survival curves were generated using the 118
GraphPad Prism 4 software. To determine p values for the differences in the survival curves 119 among various groups, the survival curves were compared using the software's Logrank test. To 120 determine bacteremia (CFU/ml) in the surviving mice, blood was collected daily for 5 days from 121 the tip of the tail vein, diluted in normal saline, and plated on sheep blood agar for colony 122 counting. The bacteremia value for dead mice was taken as >10 8 CFU/ml, because mice died 123 when the bacteremia exceeded 10 8 CFU/ml. The plotting and statistical analyses of the 124 bacteremia data were performed by using the GraphPad Prism 4 software and Mann-Whitney 125 nonparametric two-sample rank test. 126
127
PCh-binding inhibition assays. Microtiter wells were coated with either 10 g/ml of PCh-128 BSA, 10 g/ml of PnC or 10 7 CFU pneumococci, in TBS, overnight at 4 ºC, as described 129 previously (19). The unreacted sites in the wells were blocked with TBS containing 0.5% gelatin 130 for 45 min at room temperature. CRP diluted in TBS containing 5 mM CaCl 2 , 0.1% gelatin and 131 8 (Thermo) were used to detect bound CRP. Color was developed and the A 405 was read in a 139 microtiter plate reader, as described previously (19) . 140
RESULTS 142
At the 25 g dose, both WT and mutant CRP protect mice against infection with 10 7 CFU 143 of pneumococci. Fig. 1 (left) shows the combined results of two separate protection experiments 144 using 25 g of CRP, 10 7 CFU of pneumococci, and six mice in each of the three groups in each 145 experiment. Median survival time (the time taken for the death of 50% of mice) for mice injected 146 with bacteria alone (control group A) was 80 h. The median survival time for mice injected with 147 bacteria and WT CRP (group B) was more than 10 days. The median survival time for mice 148 injected with bacteria and mutant CRP (group C) was 176 h. The P values for the difference in 149 the survival curves between groups A and B, A and C, and B and C were 0.001, 0.02 and 0.24, 150
respectively. 151
Bacteremia values, determined every day for 5 days in each mouse from the protection 152 experiment, are plotted as scatter diagrams (Fig. 1, right) . In mice injected with bacteria alone 153 (group A), median bacteremia was approximately 2.5 x 10 3 CFU/ml of blood one day 154 postinfection. In mice injected with bacteria and either WT CRP (group B) or mutant CRP 155 (group C), median bacteremia was <10 3 CFU/ml one day postinfection in both groups. In group 156 A, bacteremia increased dramatically after day 1, and mice died once bacteremia exceeded 10 8 different from that of the control group for both days 1 and 2, the bacteremia values for mutant 164 CRP were also not significantly different from that of WT CRP for both days. 165 We concluded that both WT and mutant CRP decreased mortality and prolonged survival of 166 mice injected with 10 7 CFU of pneumococci and that the increased resistance to infection was 167 associated with the maintenance of a reduced bacteremia or a slower increase in bacteremia. The 168 results obtained from this animal model (25 g of CRP and 10 7 CFU of pneumococci) suggest 169 that the CRP-mediated protection of mice from infection is independent of the PCh-binding 170 activity of CRP. 171
172
With 5 x 10 7 CFU of pneumococci, and CRP at the 25 g dose, mutant CRP was 173 different from WT CRP in protecting mice against infection. Next, we changed the animal 174 model in which we used the same dose of CRP as in the experiment shown in Fig. 1, but  175 increased the number of pneumococci 5-fold. Fig. 2 (left) shows the combined results of two 176 separate protection experiments using 25 g of CRP, 5 x 10 7 CFU of pneumococci, and six mice 177 in each group in each experiment. The median survival time for mice injected with bacteria alone 178 (control group A) was 40 h, for mice injected with bacteria and WT CRP (group B) was 78 h, 179 and for mice injected with bacteria and mutant CRP (group C) was 46 h. In all three groups, mice 180 began dying at 40 h. In the control group, all mice died by 64 h. In the mutant CRP-treated 181 group, all mice died by 116 h. However, in the WT CRP-treated group, only 75% mice died in 182 10 days. The P values for the difference in the survival curves between groups A and B, A and 183 C, and B and C are <0.001, 0.03 and 0.003, respectively. Survival in both WT CRP-treated and 184 mutant CRP-treated groups was significantly different from the control group, but the WT CRP-185 treated group was also significantly different from the mutant CRP-treated group.
Bacteremia values, determined every day for 5 days in each mouse from the protection 187 experiment, are plotted as scatter diagrams (Fig. 2, right) . In mice injected with bacteria alone 188 (group A), one day postinfection, median bacteremia was approximately 1.9 x 10 5 CFU/ml of 189 blood. In mice injected with bacteria and WT CRP (group B), median bacteremia was 1.5 x 10 3 190 CFU/ml one day postinfection. In mice injected with bacteria and mutant CRP (group C), one 191 day postinfection, median bacteremia was 2.9 x 10 4 CFU/ml. In group A, bacteremia increased 192 dramatically by day 1, and bacteremia exceeded 10 8 CFU/ml by day 2. In mice administered WT 193 CRP, there was an increase in bacteremia past day 1, but it took 3 days to exceed 10 8 CFU/ml 194 when those mice died. Similar to the control group, in mice administered mutant CRP, 195 bacteremia increased dramatically after day 1, and bacteremia exceeded 10 8 CFU/ml by day 2. ng/ml to 50 ng/ml range because this range provided the linear part of the binding curve. We, 264 however, used 10 g/ml of mutant CRP to reassess the PCh-binding ability of mutant CRP, using 265 two different PCh-containg ligands, PCh-BSA (Fig. 5A) and PnC (Fig. 5B) , and whole live 266 pneumococci (Fig. 5C Because the dose of mutant CRP we used in the mouse protection experiments was only 6-271 times higher than that of WT CRP, and not 100-times higher, it is not possible that the PCh-272 independent protection was due to the residual PCh-binding activity of mutant CRP in case when 273 6-times higher dosage of mutant CRP was used. Although we do not know if there is an indirect, 274
PCh-independent, interaction between mutant CRP and pneumococci in vivo, the data obtained 275 from these assays suggest that the protection of mice seen with mutant CRP did not involve PCh-276 mediated interaction between CRP and pneumococci. The binding was also inhibited by dAMP although dAMP was a less effective inhibitor 286 compared to PCh, as reported previously (15). In contrast to WT CRP, the residual binding of 287 mutant CRP to PCh-BSA was completely inhibited by both PCh and dAMP (Fig. 6B) , indicating 288 that the binding of mutant CRP to PCh was most likely mediated through the phosphate group of 289
PCh. The weak binding and strong inhibitory power of dAMP suggested that mutant CRP 290 retained the ability to bind to phosphate. Similar results were obtained with PnC and 291 pneumococci for both WT and mutant CRP (Fig. 6C-F We tested the hypothesis that the mechanism of CRP-mediated protection of mice against S. 296 pneumoniae infection during the early stages of infection involves binding of CRP to PCh groups 297 present on pneumococci. We compared the protective ability of WT CRP that binds to PCh and 298 pneumococci with that of a CRP mutant that does not bind to either PCh or pneumococci, in 299 mice infected with lethal doses of pneumococci. We used three different animal model set-ups. 300
Our major findings were: 1. In the animal model using 25 g of CRP and 10 7 CFU of 301 pneumococci, both WT and mutant CRP protected mice against infection. 2. In the model using 302 25 g of CRP and 5 x 10 7 CFU of pneumococci, WT CRP protected but mutant CRP did not 303 protect mice against infection. 3. In the animal model using 150 g of CRP and 10 7 CFU of 304 pneumococci, mutant CRP was as capable as WT CRP in protecting mice against infection. 305
Thus, by using different animal model set-ups, it could be revealed that CRP works through both 306
PCh-dependent and PCh-independent mechanisms in protecting mice against early-stage 307 pneumococcal infection. 308
Previously, we initially reported that CRP-mediated protection of mice was not dependent on 309 the PCh-binding property of CRP (14), but subsequently reported that the CRP-mediated 310 protection of mice was dependent on the PCh-binding property of CRP (19). We provided an 311 explanation for these contradictory reports by indicating that the CRP mutants used in the two 312 studies were different (19): F66A/E81A in the first study and F66A/T76Y/E81A in the second 313 study. We also postulated that the contradictory findings could be due to differences in the purity 314 of the two CRP preparations employed; frozen and thawed mutant CRP in the first study and 315 freshly-purified mutant CRP in the second study (19). Our current findings, however, indicate 316 that the contradictory findings were due to the differences in the set-up of the animal model; in 317 on October 16, 2017 by guest http://iai.asm.org/ Downloaded from terms of median survival time, WT CRP was much less protective in the second study compared 318 to that in the first study. It was important that an animal model be used in which WT CRP 319 showed prolonged protection in terms of median survival time which was needed to evaluate the 320 protective ability of mutant CRP. 321
There are two different CRP mutants available, F66A/E81A and F66A/T76Y/E81A, which 322 do not bind to either PCh or pneumococci. However, the F66A/T76Y/E81A CRP mutant binds to 323 phosphoethanolamine much more avidly than F66A/E81A CRP mutant (19). To purify 324 F66A/E81A CRP, immunoaffinity chromatography is required which results in poor recovery of 325 pentameric CRP due to the use of an acidic pH buffer (14). We chose F66A/T76Y/E81A CRP 326 mutant for this study because it was easier to purify this mutant by affinity chromatography 327 using a phosphoethanolamine-agarose column with higher recovery of the purified protein. were not in the Ca 2+ -binding site. Our conclusion that CRP used a PCh-binding-independent 342 mechanism to protect mice against infection was also based on the finding that the amount of 343 mutant CRP required to protect mice against infection was the same as that of WT CRP, despite 344 the drastic difference in the avidity of binding of WT and mutant CRP to pneumococci. 345
The significance of the PCh-dependent mechanism is the initial and immediate clearance of 346 pneumococci as has been shown recently with endogenous mouse CRP (12). The definition of 347 the PCh-independent mechanism is not known. We hypothesize that the PCh-independent 348 mechanism involves first a structural change in CRP which is then followed by the interaction 349 between structurally altered CRP and factor H-bound pneumococci, as we have discussed 350 previously (4, 14, 19). This hypothesis is based on three findings. 
